FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data –– Gazyva is the only anti-CD20 monoclonal antibody to demonstrate a ...
The von Meissner Foundation was created in 1988 thanks to the legacy of Mrs Gertrude von Meissner, in memory of her daughter ...
Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") today announced that it has reached an agreement with the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan regarding ...
Neutrophil gelatinase-associated lipocalin (NGAL), a biomarker released in response to tubular injury, may serve as a noninvasive tool for measuring kidney injury. A new systematic review and ...
The FDA on Friday granted accelerated approval to elamipretide (Forzinity) as the first treatment for the ultra-rare Barth syndrome, which affects approximately 150 Americans. Elamipretide once-daily ...
Explore practical implications of new research in nephrotic syndrome, from renal biopsy and genetic testing to managing ...
Eight-year-old Abhijot Singh had been suffering from a kidney disorder. His story came to light during the Punjab floods, with NDTV running a campaign to ensure the child gets the help he needed. He's ...
Walker Burger always loved baseball, but attending the games of his favorite team, the Atlanta Braves, used to be a physical challenge. In fact, every form of exercise was difficult. Burger, 35, has a ...
The FDA has granted accelerated approval for the elamipretide injection, the first treatment for Barth syndrome in patients weighing at least 30 kg. Barth syndrome is a life threatening disease of the ...
After a tumultuous journey filled with delays and rejection, the FDA has approved Stealth BioTherapeutics’ treatment for the ultrarare disease Barth syndrome, marking the peptide as the first therapy ...
Noonan syndrome with multiple lentigines (NSML) is a rare genetic disorder that causes short stature, distinctive facial features, and clusters of dark skin spots called lentigines. But its most ...
Researchers at The Hospital for Sick Children (SickKids) have uncovered a promising new therapeutic target for Barth syndrome, a rare genetic condition with no current cure. Barth syndrome is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback